Можливі механізми стійкості пухлинних клітин до променевої і хіміотерапії

Зінченко, В. А.; Чащина, Л. І.

doi:10.7124/bc.00070D

Biopolym. Cell. 2005; 21(6):473-484.

http://dx.doi.org/10.7124/bc.00070D

Огляди

Можливі механізми стійкості пухлинних клітин до променевої і хіміотерапії

1Зінченко В. А., 1Чащина Л. І.

Інститут молекулярної біології і генетики НАН України
Вул. Академіка Заболотного, 150, Київ, Україна, 03680

Abstract

Огляд присвячено аналізу даних щодо ролі хімічних і фізичних факторів у формуванні хіміо- та радіорезистентності пухлинних клітин. Результати досліджень свідчать про те, що багато біологічних процесів, серед яких модуляція апоптозу, активація каспаз, ампліфікація гена MDR-1 та ін., складають основу формування стійкості до хіміотерапії. Проаналізовано деякі морфологічні і біохімічні особливості розвитку в клітинах пухлин вторинної радіорезистентності та розглянуто можливості її подолання.

Keywords: пухлинні клітини, радіорезистентність, хіміорезистентність, Р-глікопротеін, апоптоз

Повний текст: (PDF, російською)

References

[1] Dedenkov AN, Pelevina II, Saenko AS. Prediction of tumor response to radiation and drug therapy. M.: Meditsina, 1987; 160 p.

[2] Machak GN, Kochergina NV, Sen'ko OV, Kuznetsova AV. [The role of clinical and imaging criteria in risk assessment during preoperative chemotherapy for osteosarcoma]. Vopr Onkol. 2005;51(3):322-7.

[3] Dar'ialova SL, Pelevina II, Saenko AS. [Approaches to the individual prognosis of tumor reaction to radiation and drug exposures]. Med Radiol (Mosk). 1990;35(1):10-4.

[4] Serikov AA, Solyanik GI. Self-control of proliferation-differentiation processes in cell population dynamics. The Physycs of the Alive. 1998;6: 5-16.

[5] Solyanik GI, Kononenko MM, Chekhun VF, Kulik GI, Changes in the cuerin carcinoma growth in the role of resistance to cisplatin and thiophosphamide action. Exp Oncol. 1992; 14(4):68-72.

[6] Solyanik GI. Autoselection phenomenon in the population of differentiating cells: a possible mechanism of carcinogenesis. 2nd Congress of Russian biophysicists (Moscow, 23-27 Aug., 1999): Proc. M., 1999; vol 2:455-6.

[7] Stavrovskaya AA. Tumor cell in the defense. Soros Educational J. 2001; 7: 17-23.

[8] Ueda K, Yoshida A, Amachi T. Recent progress in P-glycoprotein research. Anticancer Drug Des. 1999;14(2):115-21.

[9] Zheleznova EE, Markham PN, Neyfakh AA, Brennan RG. Structural basis of multidrug recognition by BmrR, a transcription activator of a multidrug transporter. Cell. 1999;96(3):353-62.

[10] Johnstone RW, Cretney E, Smyth MJ. P-glycoprotein protects leukemia cells against caspase-dependent, but not caspase-independent, cell death. Blood. 1999;93(3):1075-85.

[11] Chekmasova AA. Induced erythroid differentiation and apoptosis in the K562 cell line resistant to a series of quinoline derivatives. Proceedings of the 13th Intern. Conf. Young Scientists: Nature. Actual. problems (26-30 Nov 2002). Moscow, 2002: 820.

[12] Stavrovskaya AA. Cellular mechanisms of multidrug resistance of tumor cells. Biochemistry (Mosc). 2000;65(1):95-106.

[13] Roninson J. B. Multidrug resistance. Encyclopedia of cancer. New York, 1997. Vol. 2: 1095-1107.

[14] Yang X, Darling JL, McMillan TJ, Peacock JH, Steel GG. Heterogeneity of radiosensitivity in a human glioma cell line. Int J Radiat Oncol Biol Phys. 1992;22(1):103-8.

[15] Ngo FOH, Jia X, Lin TC, Lee YHW. A cytosineregulated mechanism for radiation-induced changes in tumor blood perfusion. Proc. 10-th Int. Congr. Radiat. Res. (1895-1995): Abstrs. Wurzburg, 1995; Vol. 1: 270.

[16] Morozevich GE, Kozlova NI, Chubukina AN, Berman AE. [Integrin expression and invasion in vitro onco-transformed fibroblasts Syrian hamster, possessing multidrug-resistant]. Biol Membr. 2001; 18:269-74.

[17] Kozlova NI, Morozevich GE, Chubukina AN, Berman AE. Integrin alphavbeta3 promotes anchorage-dependent apoptosis in human intestinal carcinoma cells. Oncogene. 2001;20(34):4710-7.

[18] Morozevich GE, Kozlova NI, Chubukina AN, Berman AE. [The role of alphavbeta3 integrin in changes of the invasive phenotype in CP-transformed fibroblasts with multiple drug resistance]. Vopr Med Khim. 2002;48(1):111-20.

[19] Sergeev PV, Semeykin AV, Fedotcheva TA., SHimanovskiy NL. Steroid hormones as modulators of multidrug resistance status of the tumor cells. Vopr Biol Med Farm Khim. 2002; 3:10-7.

[20] Ptuskin VV, Uss AL, Demina EA, Chervonobab IuV, Milanovich NF, Tupitsyn NN, Larionova VB, Batan ZE, Kondrat'eva NE, Zmachinski? VA, Andreeva LA, Snegir' VM, Mkheidze DM, Chimishkian KL. [Superhigh-dosage chemotherapy with the transplantation of autologous hemopoietic precursor cells in patients with a prognostically unfavorable relapse and resistant course of lymphogranulomatosis]. Ter Arkh. 1997;69(10):49-55.

[21] Naovpashyna DS, Kuznetsova MA, Komarova NI, Venyamibova AG. [Chimeric oligonucleotides based on 2'-O-modified oligoribonucleotides with terminal 3'-3 'internucleotide linkage as potential inhibitors of MDR Gene Expression]. Izv Akad NAuk RF. Ser Khim. 2002; 7:1125-8.

[22] Pakunlu RI, Wang Y, Tsao W, Pozharov V, Cook TJ, Minko T. Enhancement of the efficacy of chemotherapy for lung cancer by simultaneous suppression of multidrug resistance and antiapoptotic cellular defense: novel multicomponent delivery system. Cancer Res. 2004;64(17):6214-24.

[23] Kerr JF, Winterford CM, Harmon BV. Apoptosis. Its significance in cancer and cancer therapy. Cancer. 1994;73(8):2013-26.

[24] Bergman PJ, Harris D. Radioresistance, chemoresistance, and apoptosis resistance. The past, present, and future. Vet Clin North Am Small Anim Pract. 1997;27(1):47-57.

[25] Fil'chenkov AA, Stoika RS. Apoptosis and cancer. Kyiv, Morion, 1999; 184 p.

[26] Okada H, Mak TW. Pathways of apoptotic and non-apoptotic death in tumour cells. Nat Rev Cancer. 2004;4(8):592-603.

[27] Kvetnoy IM, Polyakova VO, Trofimov AV, Yuzhakov VV, Yarilin AA, Kurilets ES, Mikhina LN, Sharova NI, Nikonova MF. Hormonal function and proliferative activity of thymic cells in humans: immunocytochemical correlations. Neuro Endocrinol Lett. 2003;24(3-4):263-8.

[28] Philchenkov A, Zavelevich M, Kroczak TJ, Los M. Caspases and cancer: mechanisms of inactivation and new treatment modalities. Exp Oncol. 2004;26(2):82-97.

[29] Luk'ianova NIu, Kulik GI, Chehun VF. [Role of the p53 and bcl-2 genes in apoptosis and drug resistance of tumors]. Vopr Onkol. 2000;46(2):121-8.

[30] Holcik M, Korneluk RG. XIAP, the guardian angel. Nat Rev Mol Cell Biol. 2001;2(7):550-6.

[31] Yarilin AA. The system of cytokines and principles of its functioning in normal and pathological conditions. Immunologiia. 1997; 5:7-14.

[32] Baryshnikov AYu, Stepanova EV. Molecular biomarkers in diagnosis of drug resistance. Allergiya, astma i klin, immunologiya. 2000; 1:23-7.

[33] Biological methods of cancer treatment, M.: Meditsina, 2002; 936 p.

[34] Ponomarev VB, Rumyantsev AG. Theoretical bases and prospects of gene therapy in hematology and oncology. Gematol Transfuziol. 2002; 1:29-9.

[35] Molchanov OE, Karelin MI, Zharinov GM. Modern trends in the use of drugs recombinant interleukin-2 in oncology. Tsitokiny i Vospalenie. 2002; 1(3):38-47.

[36] Paltsev MA, Ivanov AA. Cell-cell interactions. M.: Meditsina, 1995. 224 p.

[37] Ng CS, Novick AC, Tannenbaum CS, Bukowski RM, Finke JH. Mechanisms of immune evasion by renal cell carcinoma: tumor-induced T-lymphocyte apoptosis and NFkappaB suppression. Urology. 2002;59(1):9-14.

[38] Pertseva TA, Konopkina LI. Interferons and their inductors. Ukr Khimioterap Zh. 2001. 3(2):31-6.

[39] Garib FYu, Rizopulu AP, Aripova GU. Synergy in the induction of interferon. Med Immunol. 2004; 2:46-54.

[40] Kossman SE, Scheinberg DA, Jurcic JG, Jimenez J, Caron PC. A phase I trial of humanized monoclonal antibody HuM195 (anti-CD33) with low-dose interleukin 2 in acute myelogenous leukemia. Clin Cancer Res. 1999;5(10):2748-55.

[41] Kozlov VK, Smirnov MN, Egorova VN, Lebedev MF. Correction immunoreactivity of recombinant IL-2: A guide for physicians. St. Petersburg: Izd St-Pereb Univ. 2001; 24 p.

[42] Kopnin BP. Targets of oncogenes and tumor suppressors: key for understanding basic mechanisms of carcinogenesis. Biochemistry (Mosc). 2000;65(1):2-27.

[43] Schwartz MA, Baron V. Interactions between mitogenic stimuli, or, a thousand and one connections. Curr Opin Cell Biol. 1999;11(2):197-202.

[44] Browder T, Butterfield CE, Kr?ling BM, Shi B, Marshall B, O'Reilly MS, Folkman J. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res. 2000;60(7):1878-86.

[45] Atzpodien J, Kirchner H, Bergman L. 13-c-s- retinoic acid, IFN-alfa and chemotherapy in advanced renal cell carcinoma: results of a prospectively randomized trials of the German Cooperative Renal Carcinoma Immunotherapy Group. Proc Ame Soc Clin Oncol. 1999; 18: 1727-35.

[46] Molchanov OE, Karelin MI, Popovich AM. Treatment of hormone-refractory prostate cancer by combination doxorubicin and Betaleukin. Coll. scientific. tr. Act Vopr Urology Oncology. St. Peterbur, 2001:256-8.

[47] Legha S. A phase II study of biochemotherapy using interleukin- 2 (IL-2) + interferon alfa-2a (IFN) in combination with cisplatin (C) vinblastine (V) and DTIC (D) in patients with metastatic melanoma. J Clin Oncol. 1998; 16: 1752-9.

[48] Trufakin VA, Shurlygina AV. Cytokines and biorhythms. Med Immunol. 2001; 3, (4):477-486.

[49] Yarlin AA, Sharova NI, Dzutsev AKh. The interaction of T-lymphocytes and epithelial cells in thymus. Immunologiia. 1999; 4:15-20.

[50] Lukyanova NY, Kulik GI, Yurchenko OV, Shatrova KM,Vorobyova LI, Svintitsky VS, Evtushenko GV, Chekhun VF. Expression of p53 and Bcl-2 proteins in epithelial ovarian carcinoma with different grade of differentiation. Exp Oncol. 2000; 22(1-2):91-3.

[51] Komarov PG, Komarova EA, Kondratov RV, Christov-Tselkov K, Coon JS, Chernov MV, Gudkov AV. A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. Science. 1999;285(5434):1733-7.

[52] Sablina AA, Chumakov PM, Levine AJ, Kopnin BP. p53 activation in response to microtubule disruption is mediated by integrin-Erk signaling. Oncogene. 2001;20(8):899-909.

[53] Lukash LL. The regulation of a variability of somatic mammalian cell genome under the influence of exogeneous biological factors. Biopolym Cell. 2004; 20(1-2):93-105.

[54] Lee JM, Bernstein A. p53 mutations increase resistance to ionizing radiation. Proc Natl Acad Sci U S A. 1993;90(12):5742-6.

[55] Sun J, Chen Y, Li M, Ge Z. Role of antioxidant enzymes on ionizing radiation resistance. Free Radic Biol Med. 1998;24(4):586-93.

[56] Kopnin PB, Ivanov AV, Il'inskaia GV, Sablina AA, Kopnin BP, Chumakov PM. [The protective role of p53 in Ras-induced transformation of REF52 cells]. Mol Biol (Mosk). 2003;37(3):458-71.

[57] Kalinina EV, Saprin AN, Solomka VS, Shcherbak NP, Chermnykh NS, Piruzian LA. [Role of the antioxidant system and redox-dependent regulation of transcription factors bcl-2 and p53 in forming resistance of human K562 erythroleukemia cells to doxorubicin]. Vopr Onkol. 2001;47(5):595-600.

[58] Yarilin AA, Belyakov IM. Cytokines in the thymus: production and biological effects. Curr Med Chem. 2004;11(4):447-64.

[59] Titova IV, Sergeev VG, Yarilin AA, Akmaev IG. Expression of neuronal and inducible nitric oxide synthases in the thymus under normal conditions and after administration of bacterial endotoxin. Bull Exp Biol Med. 2002;134(4):407-10.

[60] Kvetnoy IM, Polyakova VO, Trofimov AV, Yuzhakov VV, Yarilin AA, Kurilets ES, Mikhina LN, Sharova NI, Nikonova MF. Hormonal function and proliferative activity of thymic cells in humans: immunocytochemical correlations. Neuro Endocrinol Lett. 2003;24(3-4):263-8.

[61] Yarlin AA. Apoptosis and its place in the immune processes. Immunologiia. 1996; 6:10-23.

[62] Khaitov RM., Pinegin BV. Basic principles of immunomodulating therapy. Allerg Astma, Immunol. 2000; 1:17-22.

[63] Chowdhary SA, List AF. Drug resistance: overview of mechanisms. Encyclopedia of Cancer. New York, 1997. Vol. 1: 610-20.

[64] Levchenko A, Mehta BM, Niu X, Kang G, Villafania L, Way D, Polycarpe D, Sadelain M, Larson SM. Intercellular transfer of P-glycoprotein mediates acquired multidrug resistance in tumor cells. Proc Natl Acad Sci U S A. 2005;102(6):1933-8.

[65] Chekhun VF, Zinchenko VA, Kulik I, Solyanik GI. On the question of radioresistance of tumor cells. III Congress of CIS oncologists and radiologists: Proceedings of the Congress (25-28 May 2004). Minsk, 2004; Pt 1:353.

[66] Bischof M, Huber P, Stoffregen C, Wannenmacher M, Weber KJ. Radiosensitization by pemetrexed of human colon carcinoma cells in different cell cycle phases. Int J Radiat Oncol Biol Phys. 2003;57(1):289-92.

[67] Bunting KD. ABC transporters as phenotypic markers and functional regulators of stem cells. Stem Cells. 2002;20(1):11-20.

[68] Woodburn JR. The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther. 1999;82(2-3):241-50.

[69] Lammering G, Valerie K, Lin PS, Hewit TH, Schmidt-Ullrich RK. Radiation-induced activation of a common variant of EGFR confers enhanced radioresistance. Radiother Oncol. 2004;72(3):267-73.

[70] Iyer R, Thames HD, Tealer JR, Mason KA, Evans SC. Effect of reduced EGFR function on the radiosensitivity and proliferative capacity of mouse jejunal crypt clonogens. Radiother Oncol. 2004;72(3):283-9.

[71] Chakravarti A, Dicker A, Mehta M. The contribution of epidermal growth factor receptor (EGFR) signaling pathway to radioresistance in human gliomas: a review of preclinical and correlative clinical data. Int J Radiat Oncol Biol Phys. 2004;58(3):927-31.

[72] Marples B, Cann NE, Mitchell CR, Johnston PJ, Joiner MC. Evidence for the involvement of DNA-dependent protein kinase in the phenomena of low dose hyper-radiosensitivity and increased radioresistance. Int J Radiat Biol. 2002;78(12):1139-47.

[73] Baraboi VA, Gress VE. Stress proteins: the nature and the biological role in mammalians. Aktual. probl. meditsiny i biologii. 1988; 2: 420-432.

[74] Stress proteins in biology and medicine. Eds R. J. Marimoto, A. Tiesberes, C. Georgopuos. New York: Cold Spring Harbor Lab. publ., 1991; 50 p.

[75] Skulachev VP. The laws of bioenergetics. Soros Educational J. 1997;1:9-14.

[76] Skulachev VP. Evolution, mitochondria and oxygen. Soros Educational J. 1999;9:4-9.

[77] Baraboy VA. Cellular stress, stress proteins and the stability of living systems. Actual problems of medicine and biology. 1993; 1: 12-8.

[78] Roll DE, Murphy BJ, Laderoute KR, Sutherland RM, Smith HC. Oxygen regulated 80 kDa protein and glucose regulated 78kDa protein are identical. Mol Cell Biochem. 1991;103(2):141-8.

[79] Zinchenko VA. Patterns and mechanisms of formation and overcome radioresistance of tumor cells. Auth Thesis. ... dr biol nauk. Kiev, 1999; 35 p.

[80] Fortin A, Raybaud-Diog?ne H, T?tu B, Deschenes R, Huot J, Landry J. Overexpression of the 27 KDa heat shock protein is associated with thermoresistance and chemoresistance but not with radioresistance. Int J Radiat Oncol Biol Phys. 2000;46(5):1259-66.

[81] Barabo? VA, Kulik GI, Zinchenko VA, Korol' VI. [Thiol group content in blood serum and in tumor tissue of rats with intact and radioresistant variants of Guerin carcinoma]. Ukr Biokhim Zh. 1996;68(1):61-5.

[82] Baraboi VA, Bilokin YuM, Zinchenko VA. [Features response to radiotherapy radioresistant variant Guerin carcinoma rats]. Ukr RAdiol Zh. 1998; 6(1):67-9.

[83] Lee HC, Kim DW, Jung KY, Park IC, Park MJ, Kim MS, Woo SH, Rhee CH, Yoo H, Lee SH, Hong SI. Increased expression of antioxidant enzymes in radioresistant variant from U251 human glioblastoma cell line. Int J Mol Med. 2004;13(6):883-7.

[84] Popovskaya TYa. Immunotherapy - the current standard drug treatment for kidney cancer. Mezhdunar Med Zh. 2004;2:93-5.

[85] Asanuma K, Moriai R, Yajima T, Yagihashi A, Yamada M, Kobayashi D, et al. Survivin as a Radioresistance Factor in Pancreatic Cancer. Jap J Cancer Res. 2000;91(11):1204–9.

[86] missed

[87] Lehnert S, Vestergaard J, Batist G, Aloui-Jamali MA. Radiation resistance in a melphalan-resistant subline of a rat mammary carcinoma. Radiat Res. 1994;139(2):232-9.

[88] Zinchenko VA, Kulik GI, Solyanik GI. Cross radio and chemoresistance of cancer. Proceedings of the X Congress of oncologists of Ukraine (10-12 Oct 2001 ). Yalta, 2001:39-40

[89] Baraboi VA, Zinchenko VA, Gavrylenko MF, Bobro LI, Bondaruk OS Trutneva IE. Thermo Radiotherapy in oncology. Ukr RAdiol Zh. 1995; 3(4):372-80.

[90] Zinchenko VA. Regularities and mechanisms of the combined effect of hyperthermia and radiation on the tumor cells. Biopolym Cell. 1998; 14(2):93-8.

[91] Ganul VL, Barabo? VA, Zinchenko VA, Segeda TP. [The cytokinetic characteristics of DMBA-induced tumors in rats under different variants of thermoradiotherapy]. Vopr Onkol. 1992;38(11):1376-9.

[92] Baraboy VA, Tanzura TV, Kovalenko LS, Zinchenko VA, Lawentchuk GJ. Morphometric characteristic of cell culture L929 after the termic and radiation action. Biopolym Cell. 1999; 15(1):38-42.

[93] Kovalenko MV, Zinchenko VA, Baraboi VA. Taxol as radio sensitizing agent. Farmatsevt Zh. 1999; 1:52-8.

[94] Zinchenko VA, Grynevych YuYa, Beresh I. Possibilities increased sensitivity of malignant tumors to radiation therapy using concentrate minerals. Ukr Radiol Zh. 1998; 6(1):59-62.